Every 10-Q that Sera Prognostics, Inc. (SERA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SERA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SERA filings page.
Sera Prognostics reported minimal revenue of $30 thousand for the quarter and $44 thousand for the first half of 2026, while operating expenses were $10.0 million for the quarter and $19.4 million year‑to‑date, resulting in a first‑half net loss of $17.5 million and an accumulated deficit of $329.3 million.
Cash and cash equivalents were $4.4 million and marketable securities were $75.9 million as of June 30, 2026, with total assets of $86.7 million and no debt beyond lease obligations. Management states that, after a restructuring and cost‑reduction program, existing cash resources are expected to fund operations through 2029.
To shift from a research‑heavy to a commercialization‑focused model for its PreTRM preterm‑birth test, Sera recorded $1.3 million of restructuring costs and reduced headcount by 18%, while planning material reductions in future research and general and administrative spending. Strategically, the company highlights new payer engagement, an Illinois Medicaid mandate for proteomic preterm‑birth testing, additional PRIME and AVERT clinical data, and a new $40.0 million at‑the‑market equity facility supporting potential future capital raises.
Sera Prognostics reported another early-stage quarter with very limited revenue and ongoing losses while highlighting a strong cash position and cost-cutting plans. For the three months ended March 31, 2026, revenue was $14 thousand, down from $38 thousand, and net loss was $8.4 million, or $0.17 per share.
Total assets were $93.5 million, including $4.2 million in cash and equivalents and $82.6 million in marketable securities, with stockholders’ equity of $67.6 million. The company is refocusing from research to commercialization of its PreTRM test, cutting about 18% of its workforce and expecting roughly $1.3 million in severance costs and about $9.6 million in 2027 cost savings. Management believes existing liquidity can fund operations through 2029.
Sera Prognostics (SERA) filed its Q3 2025 report, highlighting modest revenue and a continued focus on funding and operations. Revenue was $16 thousand for the quarter and $71 thousand year-to-date. The company reported a Q3 net loss of $7.8 million and a year-to-date net loss of $24.0 million, driven by operating expenses of $9.0 million in the quarter.
Liquidity strengthened earlier in the year from a February 2025 underwritten offering, delivering $53.6 million in net proceeds. As of September 30, 2025, cash, cash equivalents and marketable securities totaled $102.4 million, with total assets of $108.1 million and stockholders’ equity of $82.2 million. Operating cash used year-to-date was $19.5 million. Deferred revenue stood at $20.3 million, reflecting contractual arrangements to be recognized upon delivery of test results. The company amended and extended its headquarters lease in September 2025, with a noncurrent operating lease obligation of $2.4 million.